CRNM indicates clinically relevant nonmajor bleeding.

*Thirty-two patients to 5 mg, 30 patients to 10 mg, 33 patients to 20 mg.

†In stage IV lung cancer patients, VTE was significantly reduced (3.5% vs 10.2%; odds ratio, 0.32; 95% CI 0.09-0.98; P = .032).